ABSTRACT: Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms. V C 2017 International Parkinson and Movement Disorder Society.
In the last decade, the molecular imaging field has entered a new era of exploration into human brain diseases and has proven to be a powerful tool for investigation of the human brain, which is characterized by highly interconnected regions and networks involved in motor, cognitive, and behavioral functions. Whereas several of the recent molecular imaging approaches are still under development and probably not yet able to provide definitive answers, they represent valuable tools to improve our understanding of basic molecular mechanisms and pathophysiological processes underlying parkinsonian disorders. One current challenge is to identify biomarkers of early changes that predict at the group-level progression and development of selected manifestations of parkinsonian disorders. On an individual level, it is unclear how helpful molecular imaging techniques (i.e., PET and single-photon emission computed tomography [SPECT] ) may help stratify risk for developing motor and behavioral complications. This personalized medicine approach, though still in its infancy in Parkinson's disease (PD) and related disorders, has future potential for identifying subgroups of patients for targeted clinical trials of novel agents. Molecular imaging, with newly developed radiopharmaceuticals, now has increased potential to reveal underlying pathological processes, such as changes in receptors (e.g., dopaminergic and nondopaminergic), blood flow, metabolism, neuroinflammation, and abnormal protein deposition. Furthermore, some molecular imaging measures may provide biomarkers of target engagement or efficacy for clinical trials. Whereas most imaging studies focused on CNS abnormalities, a few interesting studies imaged peripheral organs in PD, 1 raising the issue of their practical value. Although most neuroimaging investigations focused on PD, some have addressed the atypical parkinsonisms.
This knowledge gap certainly creates the need for new molecular imaging approaches and biomarkers for these atypical parkinsonian disorders still not sufficiently understood. In this article, we will provide an overview of high-affinity radiotracers and molecular imaging advances and how these approaches have had an impact in understanding PD and atypical parkinsonisms.
Molecular Imaging of PD and Its Progression
What Have We Learned From Imaging the Dopaminergic System?
Degeneration of nigrostriatal neurons is responsible for most of the classical motor manifestations of early PD. The underlying pathophysiology in PD includes asynuclein deposition in cytoplasmic inclusions, called Lewy bodies, found in residual neurons in areas such as the SNpc, but a-synuclein also may be deposited in dystrophic neurons in striatal or cortical regions (Lewy neurites). Projection neurons like nigrostriatal afferents have long, poorly myelinated axons and may be particularly vulnerable; Lewy neurites may appear before cell body damage. 2 Although dopamine levels ( Fig. 1 ) cannot be measured directly using imaging, several approaches can be used to assess altered function of nigrostriatal dopaminergic nerve terminals (Fig. 2) . The most widely accessible approach is the use of a marker for the dopamine transporter (DAT). Several positron-or photon-emitting molecules are available for use with PET or SPECT, respectively. These ligands have varying degrees of selectivity for the DAT over other monoamine reuptake transporters, and pharmacokinetic profiles differ from one tracer to another.
FIG. 1.
Ascending nigrostriatal (red), mesolimbic (green), and mesocortical (blue) dopaminergic pathways.
This may be of some practical importance because some tracers (e.g.,
123
I-b-CIT;
I-(-)-2b-carbomethoxy-3b-(4-iodophenyl)tropane) do not reach steady state for several hours, mandating patients to return for imaging the day following tracer injection, whereas others ( Tc, which is an isotope that is widely used in clinical nuclear medicine. Striatal DAT binding correlates with loss of nigrostriatal dopamine terminals, but may only correlate with nigral neurons when that loss does not exceed 50%, 3 whereas direct imaging of midbrain uptake correlates with residual nigral neurons 4 ; thus, striatal DAT may not reflect disease progression beyond mild-to-moderate disease. 3, 5, 6 Striatal or nigral uptake may therefore be a useful imaging biomarker.
A second approach to determining the integrity of the presynaptic dopaminergic terminal is to study binding to vesicular monoamine transporter type 2 (VMAT2). VMAT2 is responsible for packaging monoamines into their appropriate synaptic vesicles, and binding is accordingly not specific to dopamine neurons. However, more than 90% of striatal VMAT2 binding is to dopaminergic nerve terminals. VMAT2 binding is typically studied with 11 C-dihydrotetrabenazine (DTBZ), which is not widely available, and studies can therefore only be performed at a few sites. However, an F 18 -labeled radiotracer is now commercially available, increasing the accessibility of these measures. VMAT2 binding may be less subject to regulation than DAT binding, 7 but this remains controversial. 8 It may have some sensitivity to vesicular dopamine levels, such that VMAT2 binding may be increased in the rare situation where nerve terminals are preserved but are depleted of dopamine. 9 The original means of studying dopaminergic function was with the use of [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] F-fluoro-L-dopa, which, like levodopa, is taken up by monoaminergic neurons, decarboxylated to (fluoro)dopamine, and, in the healthy brain, packaged in synaptic vesicles. Also, analogous to markers for DAT and VMAT2, fluorodopa uptake declines with disease progression and weakly inversely correlates with clinical severity, at least for mild-to-moderate degrees of disease severity. 3 However, the interpretation of fluorodopa scans is somewhat more complicated, in that uptake reflects not only the (unidirectional) decarboxylation of fluorodopa to fluorodopamine, but also the egress of trapped fluorodopamine from synaptic vesicles. This can be used to estimate dopamine turnover, which increases with disease severity. 10, 11 All of these presynaptic markers of dopaminergic function show a very similar pattern in PD, with asymmetric involvement of the striatum, and a rostralcaudal gradient in which the posterior putamen is maximally affected and the caudate nucleus least. Whereas this rostral-caudal gradient is preserved throughout the course of the illness, 12 the decline in 
dopaminergic markers over time is better described by an exponential, rather than a linear, relationship, where the majority of change in the putamen has taken place typically within the first 5 years, akin to postmortem observations, 12 which have demonstrated almost total loss of tyrosine hydroxylase immunoreactivity within this time. 6 Concurrent studies of multiple markers reveal that in early disease stages (H & Y stage I), the threshold for clinical manifestations was 29% to 44% of normal values for DAT binding, 38% to 49% for VMAT2 binding, and 48% to 62% for fluorodopa uptake. 13 The more-severe involvement of DAT binding may, in part, reflect downregulation of the DAT in early disease, whereas lesser involvement of fluorodopa uptake may reflect upregulation of decarboxylase activity in surviving dopamine neurons and/or expression of decarboxylase by serotonergic neurons. In studies conducted in nonhuman primates with unilateral internal carotid infusion of different doses of MPTP, it was found that the loss of only 30% to 35% of striatal terminals in nonhuman primates were able to generate motor parkinsonism and perhaps, more important, motor parkinsonism correlated with the nigral cell counts rather than the terminal field measures. 14 In these animal models, [ C-DTBZ correlated with striatal dopamine and fiber density, a reflection of terminal field function, but interestingly only correlated with nigral cell number within a limited range of cell loss (less than 50%), 3 as mentioned also above. In contrast, whereas PET measures of midbrain uptake of either VMAT2 or DAT correlated well throughout the full range of severity of nigrostriatal injury with stereologic counts of nigral dopaminergic neuronal cell bodies, 4 midbrain uptake of fluorodopa did not, thus suggesting that the midbrain measures may provide a better biomarker of severity of nigrostriatal injury. Other studies as well showed evidence that serial assessments with multiple markers provide an effective approach to evaluate evolution of dopaminergic depletion in MPTP monkeys. 15, 16 In a cohort of patients with sporadic PD studied longitudinally over several years, de la FuenteFernandez and colleagues 17 estimated that VMAT2 binding declined 17 years before disease onset, followed by DAT binding 13 years before, whereas decline in fluorodopa uptake occurs last, only 6 years 
before disease onset. However, whereas fluorodopa uptake does not decline until later, dopamine turnover increases relatively early, an estimated 8 years before disease onset in sporadic PD, 10 and years or even decades before the expected age of onset in patients with LRRK2 mutations. 18 Consistent with the latter observation, imaging studies have shown evidence of dopaminergic dysfunction in subjects with a number of pathogenic mutations. The A53T and A53E mutations in the alpha-synuclein gene (SNCA) can be associated with early, relatively symmetrical defects in presynaptic dopaminergic function. 19, 20 Additionally, recessive Parkin [21] [22] [23] and PINK1 19 mutations appear to be mostly associated with symmetrical dopaminergic losses, whereas in carriers of more-frequent LRRK2 and GBA mutations, the dopaminergic defect is practically indistinguishable from that of sporadic PD. 19, 24 In GBA-associated PD, the severity of dopaminergic dysfunction is related to the degree of glucocerebrosidase enzymatic activity reduction induced by the specific GBA mutation: Carriers of mild mutations (e.g., N370S) overlap with PD noncarriers, whereas PD carriers of severe mutations (e.g., L444P) have a similar phenotype to dementia with Lewy bodies. 25 Many investigators have proposed that dopamine release may also be a valid method to evaluate dopaminergic functions. This can be estimated by exploiting ( Fig. 2) 
transplanted PD patients who developed GIDs. 32, 33 GIDs were markedly attenuated by systemic administration of 5-HT 1A agonist buspirone, which, by reducing transmitter release from serotonergic neurons, may suggest that dyskinesias were likely related to the serotonergic hyperinnervation. Phosphodiesterase 10A (PDE10A) has a key role in the regulation of dopaminergic signaling in striatal pathways and in promoting neuronal survival. PDE10A is a basal ganglia expressed dual substrate enzyme, which regulates cyclic adenosine monophosphate and cyclic guanosine monophosphate signaling cascades. PET studies using [ 11 C]IMA107, a biomarker of PDE10A in vivo, have demonstrated reduced striatal levels of PDE10A, which correlated with PD duration and disease burden scores such as motor disability and severity of LIDs, 34 thus confirming the complex interaction of dopaminergic and nondopaminergic mechanisms underlying the pathophysiology of PD.
Consistent with this observation, voxel-based mapping of cerebral blood flow and metabolic activity has also revealed stereotyped, spatially distributed disturbances of regional brain function in PD patients. Functional brain imaging with [ 18 F]-fluorodeoxyglucose PET has provided a means of detecting and quantifying highly specific spatial covariance patterns associated with a variety of neurodegenerative disorders, including PD. 35 The PD-related metabolic pattern (PDRP), identified in resting-state metabolic imaging data analyzed using spatial covariance mapping, is characterized by increased pallidothalamic and pontine metabolic activity, associated with reductions in premotor cortex and parietal association areas. Expression values for the PDRP measured in individual subjects correlates significantly with loss of presynaptic nigrostriatal dopaminergic integrity, as well as with independent clinical ratings of motor dysfunction. 36, 37 Notably, topographically similar metabolic network abnormalities have been recently identified in nonhuman primates with experimental parkinsonism attributed to systemic MPTP exposure. 38, 39 In a recent blinded surgical trial of gene therapy for PD, the rate of PDRP progression measured over 1 year was not affected by placebo treatment. 40 In contrast, reductions in PDRP expression have been found consistently during L-dopa therapy and STN-DBS and significantly correlated with clinical improvement. 41 This suggests that PDRP can be considered a reliable biomarker of treatment response. PDRP expression is also sensitive to network changes occurring before the appearance of motor symptoms. Expression levels of this network have recently been found to be abnormally elevated in the clinically unaffected hemisphere of early PD patients and in "preclinical" subjects with rapid eye moverment sleep behavior disorder. 36, 42 Neuroinflammation is also considered to play an important role in PD. [43] [44] [45] The etiology of cognitive decline in PD is heterogeneous. Imaging biomarker studies of cognitive impairment in PD have targeted neurotransmitter systems, pathological protein deposits, and glucose metabolic or perfusion changes. Prospective evaluation of glucose metabolic changes have shown that incident dementia initially may present as a predominant hypometabolic posterior cortical pathology involving the visual association cortex, inferior parietal and temporal regions, the posterior cingulum, and precuneus in PD. 52, 53 Subsequent progression to dementia is associated with mixed subcortical, including the thalamus and caudate nuclei, and widespread cortical changes that involve the anterior cortices as well. 52, 54 Spatial covariance mapping has been particularly useful in providing information regarding the network topography that underlies cognitive dysfunction in PD. 35 Indeed, this approach has revealed a distinct PD
cognition-related pattern (PDCP) characterized by metabolic reductions in the medial prefrontal, premotor, and parietal association regions, with relative increases in the cerebellar vermis and dentate nuclei. In cross-sectional analyses, increased PDCP expression is associated with more-severe cognitive impairment. PDCP expression is abnormally elevated, even in PD patients without evidence of cognitive impairment, and highest in those with dementia. 35 Of note, PD subjects whose executive function improved with Ldopa administration ("responders") also exhibited concurrent reductions in PDCP expression. By contrast, PD subjects showing no cognitive improvement ("nonresponders") exhibited no change in PDCP expression with L-dopa. 55 Both groups, however, exhibited significant L-dopa-mediated reductions in PDRP expression, underscoring the functional distinction between the cognitive and motor networks. These findings, together with a recent study on glucose metabolism in groups of patients along the spectrum of parkinsonism to dementia (PD, PD with dementia [PDD], DLB, and AD), support the notion that glucose metabolism patterns may reflect more the clinical syndrome than the underlying pathology. 56 An intriguing dual syndrome cognitive hypothesis has been proposed, which posits that the high frequency of frontostriatal executive dysfunction in PD may relate to common dopaminergic deficits, 57, 58 and that the development of dementia is associated with more widespread and posterior cortical changes secondary to additional pathologies, including cholinergic deficits. 59, 60 Although dopaminergic denervation affects specific cognitive functions in PD, 58 striatal and limbofrontal dopaminergic changes are present in nondemented PD subjects, 58 but their presence is not sufficient to explain the full development of dementia in PD. 61 In contrast, greater cholinergic denervation is shown consistently in PD dementia compared to PD. 61, 62 These observations support a more complex pathophysiological model of interacting dopaminergic ( Fig. 1) and cholinergic degenerative (Figs. 3 and 4 ) changes producing cognitive dysfunctions in PD. [63] [64] [65] However, imaging studies confirmed as well a significant relationship between in vivo measures of elevated cortical and, in particular, striatal b-amyloid deposits (measured with [ 11 C]PIB) and greater cognitive impairment in PD. 66, 67 However, the risk of having an abnormal [ 11 C] PIB in PDD has a significantly different pattern in the brain demonstrated by principal components analysis compared to those with AD. 70 Together, these data indicate the relevance of b-amyloid brain deposition in PD, but suggest that this does not merely reflect the full spectrum of AD pathology.
All of these data demonstrate that neurotransmitter and proteinopathy changes have independent and incremental contributions to the cognitive syndrome in PD. 65 However, other factors (i.e., neuroinflammation) may also play a role. In fact, it has been shown that there may exist a direct relationship between bamyloid load and levels of microglial activation in PDD subjects, 71 suggesting that neuroinflammation may be an early phenomenon, before the dementia onset, and that amyloid along with microglial activation could together contribute not only to the local neuronal dysfunction, but also to the more remote neuronal disconnection. 71 Thus, for future studies, there is a need for new ligands for not only neurotransmission, in particular, norepinephrine, but also new neuroinflammatory (besides TSPO-binding tracers) and proteinopathy targets, especially tracers to visualize neurofibrillary tau and a-synuclein protein aggregates for more comprehensive understanding of the cognitive impairment syndrome in PD.
Behavioral and Affective Complications in PD What Molecular Imaging Has Taught Us About Behavioral Spectrum Disorders
There is evidence of a behavioral spectrum disorder ranging from hypodopaminergic levels responsible for apathy, anxiety, and depression, as described in the withdrawal dopaminergic syndrome to hyperdopaminergic syndrome, including impulse control disorders (ICDs), hallucinations, and psychosis. 72, 73 Often, depression may manifest before the diagnosis of PD; however, there is considerable evidence suggesting that this complication can be associated with a more widespread neurodegenerative process. Imaging reports seem to suggest involvement of both dopaminergic and serotonergic systems. Whereas studies using the DAT radioligand (i.e., TRODAT-1) found significantly higher DAT density in the striatum of depressed PD patients, 74 other investigations with SERT (i.e., [ 11 C]DASB) showed abnormal serotonergic neurotransmission in the raphe nuclei and limbic structures, which correlated with depression measures. 75 The serotonergic alteration in depression was confirmed by another PET study using 18 F-MPPF, a selective serotonin 1A receptor antagonist. 76 Apathy may also occur in up to 40% of PD patients, and, although clinically distinct from depression, the two are often
comorbid. 72 Anatomical and imaging reports have provided evidence that network abnormalities within the prefrontal-striatal circuit can lead to an apathetic behavior. Classically, apathy is the result of a disruption of "emotional-affective" mechanisms linked to the ventral striatum, ventromedial prefrontal cortex, and amygdala. 77 PET studies with D2/D3 receptor antagonist [11C]-raclopride have shown several differences in dopaminergic binding and transmission in the mesocorticolimbic system between apathetic and nonapathetic PD patients. 78 [11C]-raclopride binding potential was increased in apathetic PD patients in the orbitofrontal cortex (OFC), cingulate cortex, dorsolateral prefrontal cortex, amygdala, as well as in the striatum, implying either (reactive) increase in D2/D3 receptor expression and/or reduction in endogenous synaptic dopamine. Other PET studies with [
11 C]RTI-32, a ligand with affinity to both dopamine and noradrenaline transporters, confirmed that the degree of apathy severity was inversely correlated with [ 11 C]RTI-32 binding in the ventral striatum. 79 Taken together, these observations seem to suggest that apathy in PD may result from severe dopamine abnormalities in the mesocorticolimbic system, leading to an impaired emotion reactivity and poor decision-making processes, 77 as also demonstrated in nonhuman primate studies of apathetic behaviors after MPTP. 80, 81 However, from more recent evidence, the mechanism of apathy, depression, and anxiety in PD may be more complex and may differ according to the stage of the disease. In fact, in de novo PD, serotonergic, rather than dopaminergic, degeneration appears to play a significant role in this nonmotor triad. 82 Whereas certain behavioral complications are often inherent to the disease process, others are mainly associated with symptomatic treatments. Dopamine agonists, for example, have been implicated in the development of ICDs. 83 Susceptibility to these behavioral addictions is associated with increased striatal dopamine release [84] [85] [86] and reduced DAT binding in the ventral striatum. 87 Whereas abnormalities in dopaminergic processing in the ventral striatum are critical for the development of ICDs, prefrontal mechanisms may also play an important inhibitory role in these behaviors. Activation PET studies with H 2 [
15 O] before and after administration of a dopamine agonist in PD with and without gambling behavior found changes in brain areas implicated in impulse control and response inhibition (lateral orbitofrontal cortex, rostral cingulate zone, and amygdala). 88 Although the agonist significantly increased regional cerebral blood flow (rCBF) in these areas in healthy subjects, gamblers showed, in contrast, a significant reduction of activity. A subsequent PET study using the extrastriatal dopamine receptor ligand, [ 11 C]FLB-457, 89 found significant abnormalities in D2 receptor binding in the OFC and anterior cingulate cortex in PD patients with pathological gambling, thus confirming the role of prefrontal control in the development of ICDs. Similarly, [
18 F]fluorodopa PET has shown abnormalities in the OFC of PD patients with ICDs. 90 In PD patients, STN-DBS may also contribute to certain impulsive behavior associated with high-conflict decisions. 91, 92 An rCBF study with H 2 [
15 O] PET during a Go/NoGo task showed a relationship between motor improvement and response inhibition. In particular, STN-DBS affected response inhibition, as revealed by an increase in commission errors in NoGo trials 91 and stop signal task. 92 These behavioral changes were accompanied by changes in synaptic activity characterized by a reduced activation in the cortical networks associated with proactive and reactive response inhibition. These observations suggest that modulation of STN with DBS, although it improves motor functions, may tend in parallel to favor the appearance of certain impulsive behaviors by acting on mechanisms involved in response initiation and/or selection. 91 However, to date, the impact of DBS (and its interaction with dopamine agonist reduction) on the development of ICD is unclear and still quite controversial, given that studies using different approaches have shown conflicting results. [93] [94] [95] Fatigue is a common nonmotor symptom in PD. Recent studies have reported that PD patients with higher level of fatigue may show anticorrelated metabolic changes in cortical regions associated with the salience (i.e., right insular region) and default (i.e., bilateral posterior cingulate cortex) networks. 96 Other studies of dopaminergic and serotoninergic function in PD patients with and without fatigue demonstrated a serotoninergic denervation in the basal ganglia and related limbic circuits. 97 PD patients with fatigue had significantly lower SERT binding than patients without fatigue in the basal ganglia structure. 97 Additionally, voxel-based analysis identified reduced dopaminergic activity in caudate and insula and further SERT reductions in cingulate and amygdala in the fatigue group. All together, these findings provide the rationale for treatment strategies aiming to increase brain level of serotonin and serotoninergic transmission as potential treatment of this common complication in PD patients.
Differentiating Atypical Parkinsonisms From PD Is Molecular Imaging Helping Us?
To date, most molecular imaging studies in parkinsonism have focused on investigating either dopaminergic changes or cerebral blood flow and metabolism. PSP and corticobasal syndrome (CBS) are common forms of atypical parkinsonism (APS) and, in early
stages, can be sometimes quite difficult to diagnose given that they can overlap clinically with PD and other parkinsonian syndromes, including MSA. Previous imaging studies have reported in CBS either asymmetric hypoperfusion or reduced metabolism, mainly in the striatum, as well as parietal and frontal cortex contralateral to the affected limb. 98 CBS may also be variably associated with asymmetric striatal dopamine denervation (e.g., and Cilia and colleagues 99 . Similarly, PSP patients may present with a variable pattern of hypometabolism in the fronto-striatal-thalamic regions depending on the clinical presentation and progression. 98, 100 Families with mutations in the progranulin gene presented profound imaging changes of asymmetric hypoperfusion on SPECT and parietal atrophy. 101, 102 Subsequent work in CBS identified that hypoperfusion within the left inferior parietal lobule, including the left angular gyrus, was associated with more severe ideomotor apraxia. Voxel-based spatial covariance mapping has also been used to identify disease-specific networks for MSA, PSP, and corticobasal degeneration. 103, 104 Importantly, an automated logistic regression algorithm based on pattern expression values has been developed to aid in discriminating individuals with idiopathic PD from those with atypical parkinsonian syndromes and in differentiating among the various forms of APS. This approach had excellent diagnostic specificity in an original data set 105 and in a subsequent validation sample. 106 Other methods, such as relevance vector machine analysis, have also been used for single-case classification with promising results. 107, 108 Prospective validation studies are needed before the relative utility of these methods can be determined. Neuroinflammation may play an important role in various atypical parkinsonisms. To date, only a few studies have investigated neuroinflammation in these disorders using mainly first generation of radiotracers, that is, [ 11 C](R)PK11195. 109 Although the findings are highly suggestive, they require further confirmation.
Other studies assessed the diagnostic value of dopaminergic tracers using ( 18 F)-FP-CIT PET in differentiating PSP and MSA from PD. 110 Compared to PD, PSP and MSA have more prominent DAT loss in the anterior caudate and ventral putamen, respectively. However, it should be emphasized that the pattern of presynaptic dopaminergic impairment is not felt to reliably differentiate among various neurodegenerative forms of parkinsonism. Studies in which presynaptic dopamine markers are combined with measures of postsynaptic dopamine receptors may help differentiate PD from atypical parkinsonian syndromes, but not between these various syndromes. Except in a few highly specialized centers, neuroimaging has had a very limited diagnostic value in the differential diagnosis of PSP, CBS, and other tauopathies. For this reason, the development of PET radiotracers specific for tau represents one of the most active and challenging areas in molecular imaging.
Several Exciting new tracer developments hold the potential for in vivo markers of underlying pathology, which is of particular interest for interventions directly targeting protein aggregation. However, with increasingly diverse and sophisticated imaging approaches, it is now becoming more problematic than ever for nonexperts to assess the validity and significance of new studies. The scientific community should therefore move toward common standards and harmonization in molecular imaging. Good scientific practice criteria, including sample size, correction for multiple comparisons, and correction for the effects of age, motion, and partial volume effects, are among the most important issues to address. Anticipating excessive use of the term "biomarker" in imaging studies, we propose to use standardized terminology, which may help in the design of future experiments, especially when looking for surrogate markers in interventional studies. In line with the FDA/NIH BEST Resource (2016) propositions, a biomarker is defined as a characteristic that is measured as an indicator of a biological (pathogenic) process. A diagnostic biomarker should increase diagnostic accuracy for pathological or clinical entities
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in comparison to clinical judgment alone. In agreement with this definition, certain imaging characteristics may also serve to enrich specific features in a trial population (e.g., as a target verification tool in the case of tau PET). Monitoring biomarkers are measured serially and used to detect a change in the degree or extent of disease. This kind of imaging characteristic may serve as a biomarker that may predict clinical efficacy, but not likely to act as a surrogate endpoint given that such an imaging biomarker would not reflect unintended side effects. For PD, most valuable biomarkers would certainly be prodromal diagnostic biomarkers and monitoring biomarkers for disease progression at early/prodromal stages. For atypical parkinsonism, there often is a mismatch between clinical and pathological entities (e.g., CBS with AD pathology, PSP pathology with different clinical phenotypes). 116, 117 Therefore, diagnostic biomarkers in atypical parkinsonism should not be regarded as diagnostic for a clinical entity, unless the biomarker is pathologically validated. Though certainly fruitful, this kind of endeavor only seems feasible in a large, multicenter studies strategically focusing on the integration of postmortem information.
